Back to Search Start Over

Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.

Authors :
Keitel WA
Kester KE
Atmar RL
White AC
Bond NH
Holland CA
Krzych U
Palmer DR
Egan A
Diggs C
Ballou WR
Hall BF
Kaslow D
Source :
Vaccine [Vaccine] 1999 Oct 14; Vol. 18 (5-6), pp. 531-9.
Publication Year :
1999

Abstract

The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-1(19)) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-1(19) were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-1(19), including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-1(19) occurred in 5/16, 9/16 and 0/8 subjects given 20 microg of MSP-1(19), 200 microg of MSP-1(19), and control vaccines (hepatitis B or Td), respectively. Both MSP-1(19) vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles.

Details

Language :
English
ISSN :
0264-410X
Volume :
18
Issue :
5-6
Database :
MEDLINE
Journal :
Vaccine
Publication Type :
Academic Journal
Accession number :
10519944
Full Text :
https://doi.org/10.1016/s0264-410x(99)00221-2